Clinical trial
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
NCT00448968 · Inverness Medical Innovations, Industry · Completed
Key facts
| NCT number | NCT00448968 |
|---|---|
| Title | The Utility of Ischemia Modified Albumin (IMA) in Sepsis |
| Official title | The Utility of Ischemia Modified Albumin (IMA) in Sepsis |
| Lead sponsor | Inverness Medical Innovations, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome, Sepsis Syndrome |
| Enrollment | 150 |
| Start date | Mar 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Mar 19, 2007 |
| Last update posted | Sep 27, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: